Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Primary Objective:

Participants Achieving an Objective Response Rate (Cheson 2007)

Secondary Objectives:

* Progression Free Survival
* Overall Survival
* Response Duration
Diffuse Large B-Cell Lymphoma
DRUG: SAR3419|DRUG: rituximab
Number of participants achieving an Objective Response Rate, 18 weeks
Number of participants with Adverse Events, Up to 6 months|Response Duration -Time, Up to 24 months after the first infusion of the last patient|Progression Free Survival -Time, Up to 24 months after the first infusion of the last patient|Overall survival -Time, Up to 24 months after the first infusion of the last patient
* The screening period = up to 4 weeks prior to the first administration of combined therapy
* The treatment period = 3 months of combined therapy. A safety follow-up of 42 to 49 days after the last dose of treatment is planned for all patients.
* The follow-up period: Patients who are not progressing at the end of study treatment will be followed until progression or initiation of another anti-lymphoma therapy. All patients will be followed for two years to evaluate survival.